8 Best CBD Stocks to Buy Right Now
The CBD sector is showing signs of entering a more mature and sustainable growth phase. This shift is drawing renewed investor attention to CBD stocks.
Posts Tagged ‘NASDAQ:JAZZ’
10 Best European Growth Stocks to Buy
European growth stocks are getting another look as investors search for earnings growth outside the usual U.S. mega-cap playbook.
Here’s What Analysts Are Saying About Jazz Pharmaceuticals (JAZZ) Post Q1 Results
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best healthcare stocks to buy for the long term.
10 Best Healthcare Stocks to Buy for the Long Term
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2026 Earnings Call Transcript May 5, 2026Jazz Pharmaceuticals plc beats earnings expectations.
10 Best Fast Growth Stocks to Invest In Now
Fast-growth stocks are getting a fresh look as the market no longer only looks at a small group of mega-cap names.
Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most undervalued biotech stocks to buy right now. On April 10, Raymond James resumed coverage of Jazz Pharmaceuticals (NASDAQ...
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate
On February 25, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q4 revenue of $1.2 billion, exceeding consensus estimates of $1.17 billion and marking 10% year-over-year growth...
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now?
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best cheap biotech stocks to buy now.
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
11 Best Pot Stocks to Buy According to Hedge Funds
The global cannabis industry is undergoing a structural transformation as legalization expands for both medical and adult use across multiple regions.
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress
The Harbor Capital Advisors released its “Mid Cap Value Fund’s” Q4 2025 investor letter. A copy of the letter can be downloaded here.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals Fourth Quarter 2025 Earnings Conference Call.
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors.
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy
The Fed's change from higher interest rates to rate cuts has caused what Amy Y.
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial
In a statement, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said that it recorded positive results for its phase 3 clinical trial for Ziihera, in combination with chemotherapy, with...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2025 Earnings Call Transcript November 5, 2025Jazz Pharmaceuticals plc beats earnings expectations.
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility.
13 Stocks With Low Beta That Can Beat Market Volatility
In August, consumer spending and income both exceeded expectations.
Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward...
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) continues to advance its mission to transform patient lives through innovative therapies for conditions with limited treatment options.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United...
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharmaceutical leader, develops and commercializes therapies for complex conditions in oncology, neuroscience, and sleep medicine...
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there...
Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Federal Reserve's favored inflation indicator showed a modest increase in July inflation, suggesting that President Donald Trump's tariffs are having an impact on the American...
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso™ Brain Cancer Therapy
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a specialty pharmaceutical company focused on neuroscience, oncology, and rare diseases, with a global presence and products including...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the...
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email.
BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most promising future stocks according to Wall Street analysts.
12 Most Promising Future Stocks According to Wall Street Analysts
On August 18, Katie Stockton, Fairlead Strategies founder and managing partner, appeared on CNBC’s 'Squawk Box' to talk about the latest market trends and what the summer rally...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Jazz Pharmaceuticals 2025 Second Quarter Earnings Conference Call.
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating
On July 22, 2025, Morgan Stanley maintained its ‘Buy’ rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165.
10 Most Undervalued Foreign Stocks to Buy According to Analysts
The dominance of U.S.
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts.
7 Most Undervalued Pot Stocks To Buy According To Analysts
The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows.
Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval
Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts.
Jazz Pharmaceuticals’ Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year...
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)
On June 3, Needham analyst Ami Fadia reaffirmed a Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised the price target slightly from $200 to $202.
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the treatment of extensive-stage small cell lung cancer...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript May 6, 2025Jazz Pharmaceuticals plc misses on earnings expectations.
Billionaire Ray Dalio’s Bridgewater’s 10 Stock Picks with Huge Upside Potential
Up until February 18, 2025, the stock market seemed poised to replicate the 2020-2022 bull run.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Hedge Fund Resource Center
